K2 Therapeutics raises US$50m seed round and appoints Huang Ying as CEO
Singapore-based K2 Therapeutics announced on Aug 11 that it has secured a US$50 million seed round and appointed Huang Ying as its new chief executive....
This website uses cookies to improve your experience. We assume you agree, but you can opt out if you wish. Accept More Info